DiaMedica Therapeutics (DMAC) Liabilities and Shareholders Equity (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Liabilities and Shareholders Equity for 10 consecutive years, with $45.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 43.0% year-over-year to $45.0 million; the trailing twelve-month figure through Jun 2026 stood at $216.5 million (up 27.98% YoY), and the FY2025 full-year result was $61.4 million, up 32.42% from the prior year.
• Liabilities and Shareholders Equity slipped to $45.0 million in Q2 2026 per DMAC's latest filing, from $53.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $62.0 million in Q2 2023 and bottomed at $30.2 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $47.2 million across 5 years, with a median of $47.8 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity jumped 80.3% in 2022, then plunged 44.59% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $34.4 million in 2022, then soared by 57.46% to $54.2 million in 2023, then fell by 14.43% to $46.3 million in 2024, then jumped by 32.42% to $61.4 million in 2025, then retreated by 26.67% to $45.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $45.0 million, $53.1 million, and $61.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.